Daiichi Sankyo Company and Ranbaxy laboratories have entered into strategic alliance for synergistic initiative in Malaysia where Ranbaxy will market innovative products originally discovered by Daiichi Sankyo. Following Singapore, this is the company’s second marketing synergy in the ASEAN region.
Ranbaxy will market Cravit (levofloxacin), the synthetic antibacterial agent originally discovered by Daiichi Sankyo, in Malaysia from January 1, 2012. The product is currently commercialized by First Pharmaceutical in Malaysia.
Daiichi Sankyo and First Pharmaceutical have agreed to transfer the marketing rights of Cravit (levofloxacin) from First Pharma to Ranbaxy. First Pharma will continue to be Daiichi Sankyo’s marketing partner for other products (except Cravit) it had in-licensed from Daiichi Sankyo.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: